A Phase II Study of Irinotecan HCI [hydrochloride] in Patients With Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas.

Trial Profile

A Phase II Study of Irinotecan HCI [hydrochloride] in Patients With Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Irinotecan (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Dec 2011 Actual patient number is 10 according to ClinicalTrials.gov.
    • 11 Dec 2011 Planned end date changed from 1 Dec 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
    • 11 Dec 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top